Visit Website →
← Back to blog

Discrete PGx Results: EHR Teams’ First 90 Days From FHIR to CDS

October 10, 2026
Discrete PGx Results: EHR Teams’ First 90 Days From FHIR to CDS

Store pharmacogenomic genotype and phenotype data as discrete FHIR Observations, tied together under a DiagnosticReport resource, mapped to CPIC and PharmGKB phenotype definitions. Connect this data to prescribing workflows through CDS Hooks so that alerts fire at the moment of medication order entry, not buried in a PDF. The first action for most teams: define genotype and phenotype Observation profiles for your top CPIC Level A genes, then validate CDS Hooks test cases against real order scenarios before go-live.

TL;DR:

  • Store genotype, phenotype, and drug specific implications as separate FHIR Observations, recording CPIC or PharmGKB versions so updated guidance can be reapplied without retesting.
  • Reserve interruptive alerts for CPIC Level A drug pairs, filter by dose, indication, and prior tolerance, and use passive indicators for lower tier findings.
  • Test each CPIC Level A drug pair at order entry, verify uncertain diplotypes remain distinct from normal results, and confirm missing phenotype data blocks alerts.
  • Medicare coverage generally favors reactive testing tied to an active medication decision; a narrow preemptive pilot for high actionability genes can limit coverage friction.
SignalPGx
signalpgx.com
Bring PGx Results Into EHR Workflows
SignalPGx turns genetic and medication data into physician-reviewed PGx reports, with EHR integration via HL7 and FHIR standards.
Explore SignalPGx

Table of Contents

What Discrete PGx Results Are: FHIR Model and Essential Elements

Discrete PGx results are genetic findings expressed as structured, queryable data elements rather than narrative text locked inside a document. The distinction matters because a CDS engine can query a coded Observation in milliseconds, while it cannot parse a sentence buried in a scanned PDF. FHIR Observation resources are the established mechanism for storing PGx variant and genotype data, and they let CDS engines retrieve PGx findings through APIs such as CDS Hooks instead of relying on manual chart review.

The HL7 Genomics Reporting Implementation Guide lays out a layered model that separates three kinds of information, each carrying its own clinical weight:

  • Genotype Observations capture the diplotype, typically expressed as star alleles (such as CYP2C19 *1/*2), and sometimes include underlying variant-level detail using HGVS nomenclature when a specific variant call matters clinically.
  • Phenotype Observations record the derived functional status, like "poor metabolizer" or "intermediate metabolizer," computed from the diplotype according to a named mapping source.
  • Therapeutic Implication Observations state what the phenotype means for one specific drug, scoped narrowly so a single Observation never tries to cover multiple medications at once.

A DiagnosticReport or GenomicReport resource then packages these Observations together, carrying metadata such as the performing laboratory, report status, and the version of the knowledgebase used for interpretation. This packaging matters for traceability: when a reviewer or auditor needs to know exactly which CPIC guideline version produced a recommendation, the GenomicReport metadata should answer that question without requiring a phone call to the lab.

The rationale for keeping raw genetic Observations separate from therapeutic recommendations is practical rather than theoretical. Guidelines change. A phenotype assignment for a given diplotype can shift as PharmVar refines allele definitions, or a CPIC guideline update changes an actionability tier. When genotype data sits in its own Observation, untouched by interpretation logic, your system can re-run the phenotype and implication layer against updated knowledgebases without re-collecting or re-sequencing anything. Teams that instead flatten genotype and recommendation into a single note field lose that flexibility, and end up re-issuing reports from scratch every time a guideline changes. For a deeper walkthrough of mapping star alleles to clinical phenotypes, see our genotype to phenotype reporting guide.

Terminology and Normalization: Which Codes and Knowledgebases to Use

Discrete data is only useful if two systems agree on what the codes mean. Gene identifiers should use HGNC nomenclature, paired with SNOMED CT codes where a clinical concept needs broader interoperability, and star allele naming should follow PharmVar, which maintains the canonical allele definitions that CPIC and PharmGKB build upon. Open data models for pharmacogenomics point to SNOMED CT, HGNC, and PharmVar as the terminologies that make PGx data interoperable across lab, EHR, and CDS systems, rather than leaving gene and allele names as free text that each system interprets differently.

For phenotype mapping, prioritize CPIC and PharmGKB over proprietary or in-house mapping tables. CPIC phenotype mapping guidance helps standardize the translation from genotype to phenotype in a way that is reproducible across labs and widely recognized in payer policy, which matters later when you need to justify a clinical decision or a reimbursement claim.

A few practical habits keep mappings reliable over time:

  • Version everything. Store the CPIC or PharmGKB guideline version alongside every phenotype Observation so you can trace exactly which rule produced a given result.
  • Track provenance. Record which knowledgebase, version, and mapping table generated each phenotype assignment, not just the final label.
  • Plan for ambiguity. Build an explicit "indeterminate" or "uncertain function" category for diplotypes that do not map cleanly, rather than forcing an uncertain allele into the nearest known bucket.

Pro Tip: Keep a change log table that records every mapping update with its effective date; when a clinician asks why a result changed, you want a one-query answer, not an investigation.

Be cautious with combinatorial or black-box pharmacogenomic algorithms that combine multiple genes into a single proprietary score. The MolDX LCD for pharmacogenomics testing notes limited coverage support for combinatorial tests absent demonstrable independent clinical validity, which creates both a reimbursement risk and a transparency problem: when a clinician cannot see why an algorithm produced a given recommendation, trust and adoption suffer. A transparent, rule-based mapping from diplotype to phenotype to implication, auditable at every step, tends to hold up better in both clinical review and payer scrutiny.

EHR Integration Patterns and CDS Delivery

Getting discrete PGx data into the EHR is only half the job. The other half is delivering it to the clinician at the exact moment a decision is being made, which is where integration architecture matters most.

  1. CDS Hooks at medication order entry. When a clinician initiates a prescription, the EHR fires an order-select hook that queries your CDS service with the patient context. The service checks for a relevant phenotype Observation (say, CYP2C19 poor metabolizer) against the drug being ordered (clopidogrel) and returns a card with a specific recommendation rather than a generic warning. Our CYP2C19 poor metabolizer and clopidogrel guide walks through this exact scenario in clinical detail.
  2. FHIR Observation store and query layer. Phenotype and genotype Observations live in a FHIR-compliant repository, queried via standard RESTful calls (GET /Observation?patient=X&code=...). Authentication typically runs through OAuth2/SMART on FHIR scopes, which keeps access limited to authorized clinical applications rather than exposing genomic data broadly across the network.
  3. HL7 v2 ORU fallback for legacy EHRs. Many labs still deliver results as HL7 v2 ORU messages. Where the receiving EHR cannot ingest FHIR natively, middleware needs to parse the ORU segments, extract the discrete genotype and phenotype values, and translate them into FHIR Observations before they reach the CDS layer. Skipping this translation step and leaving results as scanned attachments defeats the purpose of discrete data entirely.

Pro Tip: Build a reconciliation test that checks for the presence of a discrete phenotype Observation before enabling any CDS rule tied to it; a missing Observation should block the alert, not fail silently.

Alert fatigue is the most common reason PGx CDS gets disabled within a year of launch. The fix is tiering: reserve interruptive alerts for CPIC Level A, high-actionability gene-drug pairs (CYP2C19/clopidogrel, CYP2D6/codeine, CYP3A5/tacrolimus) and use passive, non-interruptive indicators for lower-tier findings. Our CYP3A5 and tacrolimus dosing guide is a useful concrete example when designing one of these order-entry test cases, since tacrolimus dosing by phenotype is one of the cleaner CDS Hooks scenarios to build and validate first. Context filters matter too: an alert that fires regardless of dose, indication, or whether the patient already tolerated the drug will train clinicians to click past it. CDS Hooks is generally recommended as the pattern best suited to minimally invasive, context-aware alerting that respects clinical workflow instead of interrupting it indiscriminately.

Implementation Checklist and Test Plan for Storing Discrete PGx Results

A working implementation plan moves through four phases: design, ingestion, validation, and ongoing monitoring. Each phase has its own test criteria, and skipping validation to save time is the most common cause of CDS rules that silently fail in production.

Phase 1: Observation design

  1. Define a genotype Observation template with required components: gene (HGNC code), diplotype (PharmVar star alleles), and specimen/method metadata.
  2. Define a separate phenotype Observation template that references the genotype Observation, states the functional phenotype, and records the mapping source and version.
  3. Define Therapeutic Implication Observations scoped to one drug each, referencing the phenotype Observation they derive from.

Phase 2: Ingestion

  • Map incoming HL7 v2 ORU segments (OBX for discrete values, OBR for the report context) to FHIR DiagnosticReport and Observation resources through middleware.
  • Assign LIMS the responsibility of generating the initial discrete genotype call; assign middleware or an integration engine the responsibility of translating and validating that call into FHIR before EHR ingestion.
  • Reconcile every ingested report against its source message to confirm no discrete value was dropped in translation.

Phase 3: Normalization and validation tests

  • Test gene and allele mapping against a known reference panel to confirm diplotype calls resolve to the correct PharmVar nomenclature.
  • Test diplotype-to-phenotype rules against the current CPIC mapping table, including edge cases like rare alleles or diplotypes with no clear functional assignment.
  • Test handling of indeterminate results to confirm they route to a distinct "uncertain" category rather than defaulting to normal function.

Phase 4: CDS validation

  • Build medication-order test scenarios for each CPIC Level A gene-drug pair in your scope, confirming the correct alert card fires with the correct recommendation text.
  • Confirm a missing or incomplete phenotype Observation blocks the CDS rule rather than allowing a false negative (no alert when one should fire).
  • Build a rollback plan: if a CDS rule misfires in production, you need a fast path to disable that specific rule without taking down the entire PGx module.

A systematic review of pharmacogenomics clinical utility found that PGx-guided care can reduce the risk of clinically relevant adverse drug reactions by up to approximately 30% in some studies, which is the clinical case for getting this validation work right rather than treating it as a formality.

Monitoring does not stop at go-live. Build a living reanalysis process that triggers whenever CPIC or PharmGKB updates a guideline version relevant to genes in your scope. The correct response to a guideline update is never to overwrite an existing genotype Observation: create a new, versioned phenotype Observation or append a timestamped reanalysis entry, preserving the full history of what was known and when. This keeps your audit trail intact and avoids silently changing a clinical record that a prior decision was based on. Our CPIC implementation checklist walks through how to structure this governance process in more operational detail.

Workflow, Roles, and Governance Across Lab, IT, Pharmacy, and Clinicians

Discrete PGx data only stays trustworthy when ownership is explicit at every handoff. Ambiguous ownership is how mapping errors survive for years without anyone catching them.

  • Laboratory: owns the genotype call, the diplotype assignment, and the initial report generation, including which methodology and reference panel produced the result.
  • LIMS and integration team: owns the mapping from lab-internal codes to standard nomenclature (HGNC, PharmVar) and the technical translation into HL7 v2 or FHIR messages.
  • EHR/IT team: owns ingestion, Observation storage, and ensuring discrete values land in the correct structured fields rather than as an attached document.
  • Clinical informatics and pharmacy: own CDS Hooks rule configuration, alert tiering, and the clinical logic that turns a phenotype into a specific recommendation.
  • Medical director: owns final review and sign-off on reports before they reach a clinician, and should be named in the audit trail for every reportable result.

Audit trailing needs to capture who reviewed a result, when, against which guideline version, and what recommendation was issued. This record-keeping is not optional overhead: when a clinical decision is questioned months later, the audit trail is what lets your team reconstruct exactly what the system knew at the time.

Consent and patient access policies deserve their own governance track, separate from the clinical mapping logic. Decide up front whether patients see phenotype results directly through a portal or only through clinician-mediated discussion, and document that decision so it is applied consistently rather than varying by department.

Change control for mappings and CDS thresholds should run through a defined review process, not an individual developer's judgment call. A change to a phenotype mapping or an alert threshold should require sign-off from both clinical informatics and the medical director before deployment, mirroring the same rigor applied to the original validation.

Two approvals gate a clinical mapping change

Patient Access, Reporting, and Clinical Communication

A discrete data model is wasted if the clinician-facing display buries the actionable finding under technical noise. The report view a prescriber sees at the point of care should lead with the phenotype summary in plain clinical language, followed by the specific actionable recommendation, with a link to the supporting evidence for anyone who wants to go deeper.

  • Lead with the phenotype and the action, not the raw diplotype, since most prescribers need the clinical conclusion faster than the genetic detail behind it.
  • Surface normal results, not just abnormal ones. Clear communication of PGx findings, including normal results, materially affects clinician confidence and patient adherence, so a "normal metabolizer, no dose adjustment needed" line belongs in the report, not an absence of mention.
  • Write patient-facing summaries at a plain-language reading level, avoiding star allele nomenclature entirely and focusing on what the result means for the medications the patient actually takes.
  • Favor structured data sharing over PDF attachments for longitudinal reuse, since a PDF locked in a document viewer cannot be queried by a future CDS rule the way a discrete Observation can.

Pro Tip: Treat every "normal" phenotype result as a reportable finding with its own Observation, not a result that simply gets skipped, since a future clinician needs to know the gene was tested and came back normal, not just that it wasn't flagged.

Policy, Reimbursement, and Scale Considerations

Reimbursement inconsistency shapes architecture decisions more than most technical teams expect. Insurance coverage for PGx testing is inconsistent, and Medicare's MolDX program generally requires clinical actionability tied to a specific medication before covering a test, which pushes many programs toward reactive testing ordered at the point a specific drug decision is needed, rather than broad preemptive panels run before any prescription exists.

  • Reactive testing fits payer policy more comfortably since it ties the test directly to a medication decision already in progress.
  • Preemptive testing offers long-term CDS value since the data sits ready for future prescriptions, but it faces more coverage friction today.
  • Hybrid pilots, testing preemptively for a narrow set of high-actionability genes while billing reactively where possible, are a common middle path for programs managing reimbursement risk.

For labs navigating the billing side of this decision, our pharmacogenomics reimbursement guide and PGx CPT codes guide cover the coding details that affect which testing model is financially viable for a given program.

Cost-effectiveness analyses have found PGx testing cost-effective or cost-saving in a majority of studies within CPIC-supported contexts, which strengthens the case for investing in the discrete-data architecture described throughout this guide, since the clinical and financial case for PGx-guided prescribing depends on the data actually being usable at the point of care. Programs that have returned large volumes of discrete PGx indicators to EHRs have found that storage and query performance become real engineering concerns at scale, which is a strong argument for designing your Observation store and reanalysis pipeline correctly from the start rather than retrofitting it after volume grows.

For teams evaluating how specimen handling and panel selection feed into this pipeline from the lab side, our partner resource on biomarker panel selection for labs covers practical considerations for choosing which genes and panels to prioritize before data ever reaches the EHR.

How SignalPGx Supports Discrete PGx Result Workflows

We built our platform around the same principles this guide lays out: genotype and phenotype as separable, FHIR-ready data, not a static PDF. Our reporting software generates HL7/FHIR-compatible outputs designed to integrate with EHR ingestion pipelines, which means the Observation and DiagnosticReport structures your IT team needs are part of how we produce reports from the start.

  • We run living reanalysis that updates recommendations as CPIC and PharmGKB guidelines change, rather than leaving a report frozen at the moment it was first issued.
  • We maintain an audit trail with medical-director review built into the report generation process, supporting the governance and sign-off requirements clinical teams need.
  • We offer white-label infrastructure so labs can deploy branded PGx reporting services without building the underlying evidence-fusion and interpretation engine in-house.

During procurement, we recommend evaluating any reporting vendor specifically on how its output maps to FHIR Observation and DiagnosticReport structures, since that mapping determines how much custom middleware might be needed later. For a deeper look at designing the CDS implementation checklist around a CPIC foundation, our CPIC implementation checklist guide is a useful companion to this article, and the practical CDS implementation guidance from our partner at One For All Medical Billing covers operational patterns worth reviewing alongside it.

Author Perspective: Priorities for the First 90 Days of an EHR PGx Project

The teams that struggle with PGx implementation almost always over-engineer the recommendation layer before the raw data layer is solid. Start narrow: cover the CPIC Level A genes with the clearest evidence (CYP2C19, CYP2D6, CYP3A5) and get one or two CDS Hooks rules working end to end at medication order entry before expanding scope.

Resist the urge to bake final recommendations directly into stored genotype data. Store the raw diplotype as its own Observation, keep the interpretation logic in a separate, updatable knowledge layer, and let that layer evolve as CPIC and PharmGKB revise their guidance. Systems that collapse these layers into one static report end up re-issuing everything from scratch every time a guideline changes.

None of this works without clinician buy-in early. Bring pharmacy and prescribing physicians into alert design before launch, not after the first wave of override complaints. Governance that clinicians helped shape gets followed; governance imposed on them gets bypassed.

— Tarek

SignalPGx: How We Help Labs Ship Discrete PGx into the EHR

Turning a lab's genotype calls into FHIR-ready Observations that an EHR can actually use is the piece most implementation timelines get stuck on, and it is the piece we built our platform to handle. We fuse evidence from 15+ authoritative sources into physician-reviewed reports, run living reanalysis so recommendations stay current as CPIC and PharmGKB guidelines shift, and structure output to connect with EHR ingestion pipelines through HL7/FHIR.

SignalPGx

For labs that want to move faster than an in-house build allows, our white-label PGx reporting service covers deployment from Pilot through Scale and Enterprise tiers, with audit trails and medical-director review built into every report. If your team is scoping a pilot or needs an integration assessment for your existing EHR environment, reach out through our site to start that conversation.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

What Does a PGx Test Tell You?

A PGx test identifies specific genetic variants, typically expressed as star alleles, that affect how your body metabolizes certain medications. The result translates into a phenotype, such as poor or rapid metabolizer status, that helps a clinician choose a drug or dose less likely to cause an adverse reaction or treatment failure.

How Accurate Is PGx Testing?

PGx testing for well-established CPIC Level A gene-drug pairs is highly reliable when run through a certified laboratory using validated methods, since the underlying genotype calls are a direct molecular readout rather than an estimate. Accuracy concerns in practice more often come from mapping errors between genotype and phenotype than from the genetic assay itself, which is why standardized mapping to CPIC and PharmGKB matters.

Does Insurance Pay for PGx Testing?

Coverage is inconsistent and depends on the payer and the specific test. Medicare's MolDX program generally requires demonstrated clinical actionability tied to a specific medication decision, and many payers limit coverage to reactive testing ordered around an active prescribing decision rather than broad preemptive panels.

How Much Does a PGx Test Cost?

Cost varies by lab, test panel size, and whether the test is billed as reactive or preemptive, since reimbursement rules differ for each path. Several cost-effectiveness studies have found PGx testing cost-effective or cost-saving within CPIC-supported clinical contexts, which is a separate question from what a specific patient pays out of pocket, which depends on their individual coverage.

Sources

Authoritative Standards and Papers to Consult

Review the HL7 Genomics Reporting Implementation Guide for the Observation and DiagnosticReport profiles this guide references, and consult CPIC and PharmGKB directly for current phenotype mappings. The MolDX LCD for pharmacogenomics testing remains the primary reference for coverage criteria in the United States Medicare context.